Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multi-Center, Double-Masked, Randomized, Parallel-Group, Vehicle-Controlled, Phase 3 Clinical Trial to Assess the Safety and Efficacy of Reproxalap Ophthalmic Solutions (0.25% and 0.5%) Compared to Vehicle in the Conjunctival Allergen Challenge (Ora-CAC) Model of Acute Allergic Conjunctivitis

Trial Profile

A Multi-Center, Double-Masked, Randomized, Parallel-Group, Vehicle-Controlled, Phase 3 Clinical Trial to Assess the Safety and Efficacy of Reproxalap Ophthalmic Solutions (0.25% and 0.5%) Compared to Vehicle in the Conjunctival Allergen Challenge (Ora-CAC) Model of Acute Allergic Conjunctivitis

Completed
Phase of Trial: Phase III

Latest Information Update: 16 Jan 2019

At a glance

  • Drugs Reproxalap (Primary)
  • Indications Allergic conjunctivitis
  • Focus Registrational; Therapeutic Use
  • Acronyms ALLEVIATE
  • Sponsors Aldeyra Therapeutics
  • Most Recent Events

    • 08 Jan 2019 Status changed from recruiting to completed.
    • 20 Dec 2018 According to an Aldeyra Therapeutics media release, last patient has completed the dosing in this study.
    • 15 May 2018 According to an Aldeyra Therapeutics media release, Results from the trial are expected in the second half of 2018, or early 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top